[1]https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=165597[2]黄世杰.利拉鲁肽用于减肥的Ⅲ期临床试验获得阳性结果[J].国际药学研究杂志,2014,41(4):428-428.[3]FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.[4]Tsapas A,Karagiannis T,Kakotrichi P,et al.Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis[J]. Diabetes, obesity & metabolism. 2021 May 28.[5]Domenica M. Rubino et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. JAMA,January 11, 2022.[6]Weghuber Daniel,Barrett Timothy,Barrientos-Pérez Margarita et al. Once-Weekly Semaglutide in Adolescents with Obesity.[J] .N Engl J Med, 2022, undefined: undefined.
[7]https://www.lilly.com.cn/index.html#/?path=new_release&aid=332
[8]https://www.nejm.org/doi/full/10.1056/NEJMoa2206038